On Target Laboratories announces expanded indication of CYTALUX (pafolacianine) injection

Dec. 19, 2022
Injection for detection of lung cancer during surgery.

On Target Laboratories, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for the use of CYTALUX in lung cancer. 

CYTALUX is a targeted molecular imaging agent that illuminates lung and ovarian cancer intraoperatively, enabling the detection of more cancer for removal. The new indication will provide surgeons the ability to integrate CYTALUX into their treatment plan for adult patients with known or suspected lung cancer, where it previously was only approved for adults with ovarian cancer.

The label expansion is based on safety and efficacy evidence demonstrated in the ELUCIDATE Trial, a Phase 3, multi-center, single dose, open-label trial that investigated the use of CYTALUX in patients scheduled to undergo thoracic surgery for confirmed or suspected lung cancer. 

On Target Laboratories release

ID 340556497 © Svitlana Kuchina | Dreamstime.com
dreamstime_xxl_340556497
ID 76886763 © Jiri Hera | Dreamstime.com
dreamstime_xxl_76886763
ID 343308523 © Yuri Arcurs | Dreamstime.com
dreamstime_xxl_343308523
ID 146642679 © Monthira Yodtiwong | Dreamstime.com
dreamstime_xxl_146642679